Regulus Reports Third Quarter 2015 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Regulus Therapeutics (RGLS) Tops Q3 EPS by 12c
November 6, 2015 8:23 AM ESTRegulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $2.85 million.
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
... More